Shionogi to Announce Personnel Reassignment｜ 塩野義製薬 - Shionogi

Shionogi to Announce Personnel Reassignment｜ 塩野義製薬  Shionogi

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial  Reuters

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan  GlobeNewswire

Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - BioCentury

Clinical Report: Shionogi mulls next steps after underwhelming obesity readout  BioCentury

Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan - Sleep Review

Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan  Sleep Review

Is Weakness In Shionogi & Co., Ltd. (TSE:4507) Stock A Sign That The Market Could be Wrong Given ...

Is Weakness In Shionogi & Co., Ltd. (TSE:4507) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?  Simply Wall St

Shionogi presents largest global real-world evidence study of cefiderocol - The Pharma Letter

Shionogi presents largest global real-world evidence study of cefiderocol  The Pharma Letter

After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech

After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M  Fierce Biotech

Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi

Notice of Head Office Relocation｜ 塩野義製薬  Shionogi

IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrat...

IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients  Business Wire

Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...

Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024  Yahoo Finance

The public wants Medicare to cover obesity drugs - STAT

The public wants Medicare to cover obesity drugs  STAT

Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review

Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment  The Hearing Review

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement f...

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease  Business Wire

David Benadon｜ 塩野義製薬 - Shionogi

David Benadon｜ 塩野義製薬  Shionogi

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value  Shionogi

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and Academia to Tackle Infectious Diseases  Shionogi

Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Cli...

Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Climate Change and Water Security by CDP for the second consecutive year  Shionogi

Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadersh...

Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadership Award  Shionogi

Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Co...

Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Conservation and Infectious Disease Control  Shionogi

Shionogi's antiviral comes up short in global COVID-19 trial - FiercePharma

Shionogi's antiviral comes up short in global COVID-19 trial  FiercePharma

Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Includi...

Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families  Business Wire

Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter - The Pharma Letter

Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter  The Pharma Letter

Shionogi files NDA in Japan for zuranolone in MDD - The Pharma Letter

Shionogi files NDA in Japan for zuranolone in MDD  The Pharma Letter

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections  Business Wire

Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household T...

Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial  Wiley Online Library

Shionogi’s MGAT2 inhibitor improves metabolism in obesity models - BioWorld Online

Shionogi’s MGAT2 inhibitor improves metabolism in obesity models  BioWorld Online

Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia

Japan's Shionogi seeks China approval for superbug-fighting antibiotic  Nikkei Asia

Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld Online

Shionogi’s COVID-19 drug misses endpoint in global phase III  BioWorld Online

Japan's Shionogi eyes early 2025 for U.S. release of COVID pill - Nikkei Asia

Japan's Shionogi eyes early 2025 for U.S. release of COVID pill  Nikkei Asia

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1...

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults  Nature.com

Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Addre...

Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats  Business Wire

Nxera Pharma Partners with Shionogi on Insomnia Drug - TipRanks

Nxera Pharma Partners with Shionogi on Insomnia Drug  TipRanks

Shionogi presents new GLP-1R agonists for obesity and diabetes - BioWorld Online

Shionogi presents new GLP-1R agonists for obesity and diabetes  BioWorld Online

Shionogi commences Phase III monovalent Covid-19 vaccine trial - Clinical Trials Arena

Shionogi commences Phase III monovalent Covid-19 vaccine trial  Clinical Trials Arena

Shionogi's COVID Drug Stumbles, Yet Eyes Future Success - Finimize

Shionogi's COVID Drug Stumbles, Yet Eyes Future Success  Finimize

Novel COVID-19 Antiviral Ensitrelvir Provides Earlier Symptom Relief in Phase 3 Trial - Infectiou...

Novel COVID-19 Antiviral Ensitrelvir Provides Earlier Symptom Relief in Phase 3 Trial  Infectious Disease Advisor

Japan's Shionogi announces $150 M deal to develop first oral therapy for Pompe Disease - BSA bureau

Japan's Shionogi announces $150 M deal to develop first oral therapy for Pompe Disease  BSA bureau

Regulators caused breakup of potential $750 million drug deal — now they've blessed company's lat...

Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move  The Business Journals

Shionogi’s oral COVID-19 antiviral wins full approval in Japan - BioWorld Online

Shionogi’s oral COVID-19 antiviral wins full approval in Japan  BioWorld Online

New Antivirals for Today's COVID-19: Ensitrelvir and Beyond - Infectious Disease Special Edition

New Antivirals for Today's COVID-19: Ensitrelvir and Beyond  Infectious Disease Special Edition

Dialogue 2021｜シオノギ製薬（塩野義製薬） - Shionogi

Dialogue 2021｜シオノギ製薬（塩野義製薬）  Shionogi

Shionogi, Fronteo developing AI diagnostic support models for dementia, depression - BioWorld Online

Shionogi, Fronteo developing AI diagnostic support models for dementia, depression  BioWorld Online

Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in ...

Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open  Business Wire

Agency 100 2024: FCBCure - MM+M Online

Agency 100 2024: FCBCure  MM+M Online

Keiko Tone - Shionogi - Board Member - The Association of the British Pharmaceutical Industry

Keiko Tone - Shionogi - Board Member  The Association of the British Pharmaceutical Industry

SHIONOGI Infectious Disease Weeks - Shionogi

SHIONOGI Infectious Disease Weeks  Shionogi

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19  National Institutes of Health (NIH) (.gov)

Generative AI turns conference attendees into infectious disease warriors - MM+M Online

Generative AI turns conference attendees into infectious disease warriors  MM+M Online

Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership...

Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership  nagasaki-u.ac.jp

Address the problem of antimicrobial resistance (AMR) | Sustainability | Shionogi & Co., Ltd. - S...

Address the problem of antimicrobial resistance (AMR) | Sustainability | Shionogi & Co., Ltd.  Shionogi

Taiwan approves Japan-based Shionogi's influenza drug for paediatric use - BSA bureau

Taiwan approves Japan-based Shionogi's influenza drug for paediatric use  BSA bureau

Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss - BSA bureau

Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss  BSA bureau

Masahiro Fujita - Shionogi

Masahiro Fujita  Shionogi

European Commission offers hope for misunderstood intellectual disability and autism condition, F...

European Commission offers hope for misunderstood intellectual disability and autism condition, FXS  OutSourcing-Pharma.com

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana  Shionogi

Shionogi Announces Agreement With SOBI - European Pharmaceutical Manufacturer

Shionogi Announces Agreement With SOBI  European Pharmaceutical Manufacturer

Margaret Borys - Shionogi

Margaret Borys  Shionogi

Mother to Mother SHIONOGI Project - Shionogi

Mother to Mother SHIONOGI Project  Shionogi

Annual Report / Integrated Report / Environment Report | IR Library | Shionogi & Co., Ltd. - Shio...

Annual Report / Integrated Report / Environment Report | IR Library | Shionogi & Co., Ltd.  Shionogi

Partnering to Bring Meaningful Science to Patients - Shionogi

Partnering to Bring Meaningful Science to Patients  Shionogi

“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamm...

“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care.  Business Wire

Tadashi Hara - Shionogi

Tadashi Hara  Shionogi

Message from Top Management - Shionogi

Message from Top Management  Shionogi

Medium-Term Business Plan STS2030 Revision（FY2023 – FY2030） | Business Strategy | Shionogi & Co...

Medium-Term Business Plan STS2030 Revision（FY2023 – FY2030） | Business Strategy | Shionogi & Co., Ltd.  Shionogi

Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug - BSA...

Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug  BSA bureau

History - Shionogi

History  Shionogi

Shionogi Certified as the First Eco-First Company in the Pharmaceutical Industry of Environmental...

Shionogi Certified as the First Eco-First Company in the Pharmaceutical Industry of Environmentally Advanced Company  Shionogi

What we stand for: Takeki Uehara - Shionogi

What we stand for: Takeki Uehara  Shionogi

Climate Change | Environment | Shionogi & Co., Ltd. - Shionogi

Climate Change | Environment | Shionogi & Co., Ltd.  Shionogi

Nathan McCutcheon - Shionogi

Nathan McCutcheon  Shionogi

New data from Japan shows early resolution of common Covid-19 symptoms - BioPharma-Reporter.com

New data from Japan shows early resolution of common Covid-19 symptoms  BioPharma-Reporter.com

Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malari...

Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malaria  BSA bureau

Research Topics - Shionogi

Research Topics  Shionogi

“Gamma wave sound weather forecast” using “gamma wave sound” jointly developed by Pixie Dust Tech...

“Gamma wave sound weather forecast” using “gamma wave sound” jointly developed by Pixie Dust Technologies and Shionogi & Co., starts regular broadcasting on Japan’s first radio program, Bunka Broadcasting  Pixie Dust Technologies, Inc.

Taiwan FDA approves Shionogi's FETROJA for treating complicated urinary tract infections - BSA bu...

Taiwan FDA approves Shionogi's FETROJA for treating complicated urinary tract infections  BSA bureau

Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. - Shionogi

Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd.  Shionogi

Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace

Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline  BioSpace

A&O advises Shionogi on its strategic joint venture with Apnimed for the development of therapies...

A&O advises Shionogi on its strategic joint venture with Apnimed for the development of therapies for obstructive sleep apnea and other sleep disorders  A&O Shearman

Financial Highlights | Investors | Shionogi & Co., Ltd. - Shionogi

Financial Highlights | Investors | Shionogi & Co., Ltd.  Shionogi

Shionogi has been Selected as One of the Excellent Integrated Reports by the GPIF's Domestic Equi...

Shionogi has been Selected as One of the Excellent Integrated Reports by the GPIF's Domestic Equity Managers for the Third Consecutive Year  Shionogi

Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial...

Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial Disclosures (TCFD) and its participation in the TCFD Consortium  Shionogi

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus  Reuters

Antimicrobial resistance: Shionogi advocates policy change to address the public health threat - ...

Antimicrobial resistance: Shionogi advocates policy change to address the public health threat  Nature.com

The race for obesity drug assets heats up - pharmaphorum

The race for obesity drug assets heats up  pharmaphorum

Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022 - Shionogi

Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022  Shionogi

Staying ahead of antimicrobial resistance - Nature.com

Staying ahead of antimicrobial resistance  Nature.com

Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...

Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine  Fierce Biotech

Improving access to healthcare services in developing countries - Shionogi

Improving access to healthcare services in developing countries  Shionogi

WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean spor...

WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean sport  WADA

Initiatives to support people with neurodevelopmental disorders | Society | Shionogi & Co., Ltd. ...

Initiatives to support people with neurodevelopmental disorders | Society | Shionogi & Co., Ltd.  Shionogi

Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against B...

Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against BeiGene  FiercePharma

Shionogi Falls After a Panel Postpones Decision on Covid Pill - Bloomberg

Shionogi Falls After a Panel Postpones Decision on Covid Pill  Bloomberg

Shionogi’s Covid-19 Pill Ready to Move to Final Trial Phase - Bloomberg

Shionogi’s Covid-19 Pill Ready to Move to Final Trial Phase  Bloomberg

UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs - Bloomberg

UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs  Bloomberg

Shionogi Jumps After Covid-19 Antiviral Pill Seen Effective - Bloomberg

Shionogi Jumps After Covid-19 Antiviral Pill Seen Effective  Bloomberg

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral ...

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir  ACS Publications

Japanese drugmaker urges G7 to fix infectious diseases market - Financial Times

Japanese drugmaker urges G7 to fix infectious diseases market  Financial Times

Japan's Shionogi starts phase III clinical trial in Vietnam for Covid-19 vaccine - Reuters

Japan's Shionogi starts phase III clinical trial in Vietnam for Covid-19 vaccine  Reuters

Second Term Project：Mother to Mother SHIONOGI Project - Shionogi

Second Term Project：Mother to Mother SHIONOGI Project  Shionogi